{"artifact":{"id":"experiment_proposal-9722b9f2-f1ce-4c29-bd64-1ab2d3208967","artifact_type":"experiment_proposal","entity_ids":"[]","title":"Experiment Proposal (Crux): What is the evidence that blood-brain barrier (BBB) permeability changes serve as early biomarkers f [60426-210049]","quality_score":0.6,"created_by":"Theorist","provenance_chain":"[]","content_hash":"ac85ed0b5cc8ba2a374e4a0d767e8e3b77e81659541fe7b198faa28c83ed3626","metadata":{"aims":["Determine whether CAV1 upregulation in brain endothelial cells is a protective compensatory response or a pathogenic driver of BBB dysfunction in neurodegeneration","Delineate the temporal sequence of CAV1 expression changes relative to other BBB permeability markers (GFAP, NFL, claudin-5, PDGFR-β) and amyloid/tau burden"],"source":"debate_crux","question":"What is the evidence that blood-brain barrier (BBB) permeability changes serve as early biomarkers for neurodegeneration?\n\nFocus areas:\n- CSF biomarker panels for BBB dysfunction (tight junction proteins like claudin-5, zonula occludens-1; pericyte markers like PDGFR-beta)\n- Blood-based BBB permeability indicators (S100B, NFL, GFAP in plasma vs CSF)\n- Dynamic contrast-enhanced MRI measures of BBB leakage as early AD/PD markers\n- Relationship between BBB disruption and neurovascular uncoupling preceding motor/cognitive symptoms\n- Comparative utility of BBB permeability markers vs amyloid/tau PET for early detection","hypotheses":["H1: If CAV1 is compensatory/protective, then CAV1+ endothelial cells should colocalize with preserved BBB integrity markers, show anti-inflammatory gene signatures, and increase prior to detectable leakage in DCE-MRI","H2: If CAV1 is pathogenic, then CAV1+ endothelial cells should colocalize with barrier breakdown markers, pro-inflammatory transcriptomic signatures, and CAV1 expression will correlate with longitudinal BBB leakage"],"dissent_text":"CAV1 upregulation may be a compensatory protective mechanism rather than a primary pathological driv","est_cost_usd":85000.0,"persona_used":"Theorist","consensus_text":"Plasma GFAP and NFL are consistently elevated in early AD and represent the most translation-ready BBB permeability markers currently available; BBB dysfunction appears to precede or parallel amyloid  |","skill_evidence":"","_schema_version":1,"datasets_queried":["dataset-d8372bd7-eded-4ef1-adde-e0058b42cc4c","dataset-allen_brain-SEA-AD-MTG-10x","dataset-192467e0-fe96-43cb-a64f-e891cdcff111","tabular_dataset-seaad-microglia-de","dataset-clinicaltrials.gov-ad_trial_tracker","tabular_dataset-d9439233-b413-4273-a003-b14bceb146d7","dataset-geo-GSE123456","tabular_dataset-b3889491-fc25-440e-863d-bc96f9d33c51","dataset-zenodo-10-5281-zenodo-1234567","dataset-allen_brain-SEA-AD"],"protocol_summary":"Step 1: Deconvolve CAV1+ endothelial cell subpopulations from SEA-AD snRNA-seq using reanalysis with caveolin-1 as a discriminating feature, comparing NC vs early-AD vs late-AD subgroups; compute co-expression modules of CAV1 with claudin-5, PDGFR-β, GLUT1, and inflammatory genes (IL1B, TNF-α) per cell. Step 2: Stratify donors by CAV1 co-expression signature (CAV1-high-inflammatory vs CAV1-high-barrier-protective) and test for associations with ante-mortem DCE-MRI BBB leakage data and CSF/plasma GFAP, NFL, and S100B levels where available. Step 3: Validate CAV1 spatial resolution in post-mortem BA9/MTG tissue from matched donors using multiplexed RNAscope + immunofluorescence for claudin-5, PDGFR-β, and amyloid/tau pathology burden. Step 4: In an in-vitro BBB-on-chip model (iPSC-derived brain endothelial/pericyte co-culture), modulate CAV1 expression via CRISPRi (loss-of-function) and CAV1-OE (gain-of-function) to test (a) baseline trans-endothelial electrical resistance and fluorescein flux, (b) response to inflammatory challenge (TNF-α/IL-1β), and (c) recovery kinetics after insult removal. Step 5: Quantify CAV1 phosphorylation status (Y14 vs S80) in AD vs control endothelial nuclei as a biochemical read-out distinguishing caveolae-mediated transcytosis (pathogenic) from signalingadaptation (compensatory).","debate_session_id":"sess_SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426_20260426-210049","skill_invocations":[],"est_duration_weeks":16.0,"dataset_dependencies":["Allen Brain SEA-AD Single Cell Dataset","SEA-AD MTG 10x snRNA-seq","SEA-AD Differential Expression: AD vs Control (MTG)","SEA-AD Microglia Differential Expression (AD vs. Controls) — Top 20 Genes","TREM2 Expression by Cell Type","Proteomic Analysis of Neurodegeneration"],"falsification_criteria":"CAV1 upregulation would be confirmed as non-compensatory (H2) if: (a) CAV1+ endothelial cells in early-AD show no barrier-preserving gene co-expression but instead show CD31 downregulation and IL1B/TNF co-induction; (b) CAV1 expression correlates positively with concurrent DCE-MRI leakage, not preceded by it; (c) CAV1-OE in-vitro fails to improve TEER under any condition and accelerates fluorescein flux. Conversely, CAV1 is confirmed compensatory if: (a) CAV1+ cells cluster by GLUT1+/PDGFR-β+ signature in early-AD before detectable GFAP/NFL elevation; (b) DCE-MRI leakage is greater in CAV1-low endothelial clusters within the same donor; (c) CAV1-OE reduces transcytosis flux and improves recovery post-inflammatory challenge.","predicted_observations":"If CAV1 is compensatory (H1 true): CAV1-high endothelial cells will co-express barrier-preserving genes (GLUT1, SLC2A1; PDGFR-β), cluster in early-AD Braak stage donors, precede detectable GFAP/NFL elevation in CSF, and show increased TEER after CAV1-OE in-vitro with reduced post-inflammatory leakage. If CAV1 is pathogenic (H2 true): CAV1+ cells will co-express pro-inflammatory modules and vesicular trafficking genes, correlate with DCE-MRI leakage within the same donor, increase monotonically with late-AD stages, and CAV1-OE will accelerate barrier breakdown and increase fluorescein flux after cytokine challenge."},"created_at":"2026-04-27T03:19:55.796073-07:00","updated_at":"2026-04-27T03:19:55.796073-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"2f56fa35-2a7e-47d4-ad25-5709a4402434","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"Theorist"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[{"source_artifact_id":"open_question-a2a38885-4a88-4d62-a4ae-068ab9fbb347","link_type":"discriminating_experiment","strength":0.82,"evidence":"{\"confidence\": 0.82, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-55e21a3f-3ecf-4bab-9d7c-50334ae43b78","link_type":"discriminating_experiment","strength":0.92,"evidence":"{\"confidence\": 0.92, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-557e39f7-3cb6-4da9-bad0-5e8194282520","link_type":"bears_on_question","strength":0.42,"evidence":"{\"confidence\": 0.42, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-5ed8ee43-6276-4d8b-b863-f5b32c29d88e","link_type":"bears_on_question","strength":0.52,"evidence":"{\"confidence\": 0.52, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-3ea623a1-ab86-451a-9ddc-ba240648a4fa","link_type":"discriminating_experiment","strength":0.42,"evidence":"{\"confidence\": 0.42, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment_proposal-9722b9f2-f1ce-4c29-bd64-1ab2d3208967","is_canonical":true,"supersede_chain":["experiment_proposal-9722b9f2-f1ce-4c29-bd64-1ab2d3208967"]}